Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (SCYX)
NASDAQ:SCYX
SCYX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $1.66
Previous CloseN/A
Volume100.07K
Average Volume (3M)178.55K
Market Cap
$34.37M
Enterprise Value-$8.96M
Total Cash (Recent Filing)$44.78M
Total Debt (Recent Filing)$2.39M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 05, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding41,924,942
10 Day Avg. Volume109,053
30 Day Avg. Volume178,547
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.26
Enterprise Value/Revenue-2.75
Enterprise Value/Gross Profit-4.73
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$4.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe FDA clinical hold on the P3 MARIO study of Brexafemme has been lifted, allowing Scynexis to resume the study.
Financial PerformanceScynexis reported $1.4M in revenue, up 85% year-over-year, showcasing strong financial growth.
Product DevelopmentSCY-247, the next-gen fungerp wholly owned by Scynexis, is in the clinic with the P1 MARIO study.
Bears Say
Dispute And Legal IssuesThe dispute between GSK and Scynexis regarding MARIO study milestone payments of $30M continues.
Partnership And Agreement ChallengesGSK has notified Scynexis of its intent to terminate the agreement tied to a $30M milestone upon study resumption.
Revenue UncertaintyUncertainty around the timelines for Brexafemme commercial royalties and GSK's potential filing for approval in invasive fungal infections increases the revenue risk adjustment to 50%.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.66 and its highest was $1.66 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $34.37M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 13, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.05.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.2.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 41,924,942 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (376.19% Upside)
$4.00 (376.19% Upside)
Blogger Sentiment
Bullish
SCYX Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.83%
12-Months-Change
Fundamentals
Return on Equity
-37.22%
Trailing 12-Months
Asset Growth
-43.70%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Stock 12 Month Forecast
Average Price Target
$4.00
▲(376.19% Upside)
Technical Analysis
China Pharma Holdings
―
Durect
―
Rockwell Med
―
Kala Pharmaceuticals
―
China SXT Pharmaceuticals
―
Ownership Overview
4.64% Insiders
20.08% Mutual Funds
10.70% Other Institutional Investors
60.77% Public Companies and
Individual Investors